ClinicalTrials.gov Search Results 01/10/2019

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
1	NCT03552549	SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma (MK-4031-002) Study Documents:	Title Acronym: Other Ids: •C98135 •MK-4031-002 •C98-135	Terminated	•Melanoma	•Biological: PEG-Intron •Biological: INTRON A	Study Type: Interventional Phase: •Phase 2 •Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Progression-free Survival Time	Enrollment: 126 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•Merck Sharp & Dohme Corp.	•Industry	Study Start: August 5, 1998 Primary Completion: February 19, 2001 Study Completion: February 19, 2001 First Posted: June 12, 2018 Results First Posted: No Results Posted Last Update Posted: June 12, 2018	
2	NCT01462773	Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma Study Documents:	Title Acronym: Other Ids: •OSU-04105 •NCI-2011-03174	Completed	•Melanoma	•Drug: Bortezomib •Drug: Interferon Alfa-2b	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Determine Dose Limiting Toxicities (DLTs) of VELCADE When Administered in Combination With IFN-#-2b to Patients With Metastatic Malignant Melanoma. •Document Any Objective Anti-tumor Responses and Time to Tumor Progression That May Occur in Response to This Treatment Regimen.	Enrollment: 16 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Ohio State University Comprehensive Cancer Center	•Other	Study Start: January 2006 Primary Completion: October 2010 Study Completion: April 2013 First Posted: October 31, 2011 Results First Posted: December 30, 2014 Last Update Posted: January 13, 2015	•Ohio State University, Columbus, Ohio, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
3	NCT01943422	Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma Study Documents:	Title Acronym: 12-107 Other Ids: 12-107	Completed	•Melanoma	•Drug: High-dose Interferon alfa-2b •Drug: Vemurafenib	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Number of Participants with Adverse Events to determine Ph II dose •Progression Free and overall survival (Efficacy)	Enrollment: 7 Age: 18 Years and older (Adult, Older Adult) Sex: All	•John Kirkwood •Merck Sharp & Dohme Corp. •University of Pittsburgh	•Other •Industry	Study Start: October 2013 Primary Completion: November 2016 Study Completion: December 2016 First Posted: September 17, 2013 Results First Posted: No Results Posted Last Update Posted: April 3, 2018	•Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
4	NCT00746746	A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma Study Documents:	Title Acronym: Other Ids: •USA-MCI-01 •IND# 13647	Unknown status	•Melanoma	•Biological: HyperAcute vaccine •Drug: Pegylated Interferon-Alpha 2b	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •To conduct scientific studies of patient tumor and peripheral blood samples to determine the mechanism of any observed anti-tumor effect involving the immune responses to the HyperAcute® vaccine alone & combined with PEG-Intron •To determine the safety and response rate of the administration of the HyperAcute®-Melanoma Vaccine combined with PEG-Intron® into patients with recurrent, refractory, metastatic, or high risk of recurrence melanoma	Enrollment: 30 Age: 19 Years and older (Adult, Older Adult) Sex: All	•Ochsner Health System •NewLink Genetics Corporation	•Other •Industry	Study Start: June 2008 Primary Completion: June 2010 Study Completion: June 2011 First Posted: September 4, 2008 Results First Posted: No Results Posted Last Update Posted: January 13, 2011	•Ochsner Health System, New Orleans, Louisiana, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
5	NCT03435302	HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Study Documents:	Title Acronym: Other Ids: BCHMMAT001	Recruiting	•Melanoma	•Drug: Temozolomide Plus Cisplatin •Drug: High-Dose IFN-a2b	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Relapse-free survival (RFS) of high-dose IFN-a2b (HDI) and temozolomide-based chemotherapy as adjuvant therapy for resected mucosal melanoma. •Distant metastasis-free survival(DMFS) of high-dose IFN-a2b (HDI) and temozolomide-based chemotherapy as adjuvant therapy for resected mucosal melanoma. •Overall survival (OS) of high-dose IFN-a2b (HDI) and temozolomide-based chemotherapy as adjuvant therapy for resected mucosal melanoma. •Number of Participants with Adverse Events of high-dose IFN-a2b (HDI) and temozolomide-based chemotherapy as adjuvant therapy for resected mucosal melanoma	Enrollment: 204 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Beijing Cancer Hospital	•Other	Study Start: February 2014 Primary Completion: February 2018 Study Completion: February 2019 First Posted: February 16, 2018 Results First Posted: No Results Posted Last Update Posted: February 16, 2018	•Beijing Cancer Hospital, Beijing, China

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
6	NCT00525031	Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients Study Documents:	Title Acronym: Other Ids: •2005-0143 •NCI-2010-00855	Completed	•Melanoma	•Drug: Temozolomide (TMZ) •Drug: Pegylated Interferon Alpha-2b (PGI)	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Participant) •Primary Purpose: Treatment Outcome Measures: •Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) •Response to Neoadjuvant Therapy: Overall Clinical Responses	Enrollment: 55 Age: 18 Years and older (Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center •Schering-Plough	•Other •Industry	Study Start: August 2006 Primary Completion: June 2016 Study Completion: June 2016 First Posted: September 5, 2007 Results First Posted: July 2, 2017 Last Update Posted: July 2, 2017	•University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7	NCT00723710	Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600) Study Documents:	Title Acronym: Other Ids: P04600	Completed	•Melanoma	•Biological: Intron A (interferon alfa-2b; SCH 30500)	Study Type: Observational Phase: Study Design: •Observational Model: Case-Only •Time Perspective: Prospective Outcome Measures: Number of Participants Who Completed Treatment	Enrollment: 299 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Merck Sharp & Dohme Corp.	•Industry	Study Start: April 2006 Primary Completion: September 2012 Study Completion: September 2012 First Posted: July 29, 2008 Results First Posted: October 28, 2013 Last Update Posted: August 26, 2015	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
8	NCT01729663	Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Study Documents:	Title Acronym: Other Ids: CASVAC0401	Unknown status	•Cutaneous Melanoma	•Biological: CSF470 vaccine, BCG, Molgramostim •Drug: interferon alpha 2b	Study Type: Interventional Phase: •Phase 2 •Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Efficacy •security •Quality of Life •Induction of immune responses	Enrollment: 108 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•Laboratorio Pablo Cassará S.R.L. •Fundacion Sales •Agencia Nacional de Promocion Cientifica y Tecnica, Argentina •Fundacion Cancer FUCA •National Council of Scientific and Technical Research, Argentina •Instituto Nacional del Cáncer, Argentina	•Industry •Other	Study Start: April 2009 Primary Completion: December 2018 Study Completion: First Posted: November 20, 2012 Results First Posted: No Results Posted Last Update Posted: September 2, 2015	•Instituto Médico Alexander Fleming, Buenos Aires, Capital Federal, Argentina
9	NCT00049530	PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000258114 •E2602 •U10CA021115	Completed	•Melanoma (Skin)	•Biological: PEG-interferon alfa-2b	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Plasma b-FGF Level Response •Non-progression Rate (Clinical Response to Peginterferon Alfa-2b) •Progression Free Survival •Overall Survival	Enrollment: 32 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Eastern Cooperative Oncology Group •National Cancer Institute (NCI)	•Other •NIH	Study Start: September 2003 Primary Completion: August 2012 Study Completion: June 2014 First Posted: January 27, 2003 Results First Posted: June 3, 2014 Last Update Posted: October 28, 2015	•UAB Comprehensive Cancer Center, Birmingham, Alabama, United States •Lakeland Regional Cancer Center at Lakeland Regional Medical Center, Lakeland, Florida, United States •St. Joseph Medical Center, Bloomington, Illinois, United States •Graham Hospital, Canton, Illinois, United States •Memorial Hospital, Carthage, Illinois, United States •Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States •Eureka Community Hospital, Eureka, Illinois, United States •Galesburg Clinic, PC, Galesburg, Illinois, United States •Mason District Hospital, Havana, Illinois, United States •Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States •and 22 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
10	NCT01259934	Nordic Adjuvant IFN Melanoma Trial Study Documents:	Title Acronym: Other Ids: Nordic-IFN-melanoma trial	Completed	•Melanoma •Adjuvant Therapy	•Drug: Interferon-alpha2b - 1 year •Drug: Interferon-alpha2b - 2 years	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Overall survival •Relapse free survival •Safety-toxicity •Health related quality of life	Enrollment: 855 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Karolinska Institutet •Merck Sharp & Dohme Corp.	•Other •Industry	Study Start: November 1996 Primary Completion: June 2008 Study Completion: June 2008 First Posted: December 14, 2010 Results First Posted: No Results Posted Last Update Posted: December 14, 2010	•Karolinska Institutet, Karolinska University Hospital,, Stockholm, Sweden

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
11	NCT00217542	Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery Study Documents:	Title Acronym: Other Ids: •NCI-2009-00152 •YALE HIC#27409 •YALE-HIC-27409 •NCI-7317 •CDR0000441640	Completed	•Recurrent Melanoma •Recurrent Renal Cell Cancer •Stage III Melanoma •Stage IV Melanoma •Stage IV Renal Cell Cancer	•Biological: recombinant interferon alfa-2b •Drug: amifostine/ azacitidine	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Adverse event profile of azacitidine and recombinant interferon alfa-2b in patients with unresectable or metastatic melanoma and renal cell carcinoma •Maximum tolerated dose of recombinant interferon alfa-2b when administered in combination with 5-azacitidine •Correlation of promoter methylation with the level of expression of the genes •Response rate of giving recombinant interferon alfa-2b when administered in combination with 5-azacitidine in patients with metastatic melanoma and renal cell carcinoma	Enrollment: 42 Age: 18 Years and older (Adult, Older Adult) Sex: All	•National Cancer Institute (NCI)	•NIH	Study Start: July 2005 Primary Completion: July 2008 Study Completion: First Posted: September 22, 2005 Results First Posted: No Results Posted Last Update Posted: May 3, 2013	•Yale University, New Haven, Connecticut, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
12	NCT00498979	Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Study Documents:	Title Acronym: Other Ids: •CASE3Y06 •P30CA043703	Completed	•Stage IV Melanoma	•Biological: recombinant interferon alfa-2b •Drug: cisplatin •Drug: sodium stibogluconate •Drug: dacarbazine •Drug: vinblastine	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Safety of the combination of sodium stibogluconate and interferon alfa-2b with chemotherapy •Effects of sodium stibogluconate on interferon alfa-2b induced gene modulation and signal transduction pathways by measuring the serum soluble gene product •Effectiveness of sodium stibogluconate in inhibiting the protein tyrosine phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes •Pharmacokinetics of sodium stibogluconate in serum at escalating doses •Clinical response to the combination of sodium stibogluconate and interferon alfa-2b as priming for combination chemotherapy	Enrollment: 22 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Case Comprehensive Cancer Center •National Cancer Institute (NCI)	•Other •NIH	Study Start: May 2007 Primary Completion: May 2010 Study Completion: January 2012 First Posted: July 11, 2007 Results First Posted: No Results Posted Last Update Posted: September 30, 2015	•Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
13	NCT02339324	Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Study Documents:	Title Acronym: Other Ids: UPCI 14-102	Active, not recruiting	•Melanoma	•Drug: Pembrolizumab and high dose interferon alfa-2b (HDI)	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •The number of participants who experience adverse events. •Evaluate changes in immunologic biomarkers in the blood and in the tumor tissue and assess their association with resposne to treatment.	Enrollment: 30 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Yana Najjar •Merck Sharp & Dohme Corp. •University of Pittsburgh	•Other •Industry	Study Start: June 2015 Primary Completion: July 2019 Study Completion: January 2020 First Posted: January 15, 2015 Results First Posted: No Results Posted Last Update Posted: September 3, 2018	•Roswell Park Cancer Institute, Buffalo, New York, United States •Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
14	NCT01502696	Adjuvant PEG Intron in Ulcerated Melanoma Study Documents:	Title Acronym: Other Ids: •EORTC-18081 •2009-010273-20	Active, not recruiting	•Ulcerated Melanomas	•Biological: PEG IFN alfa-2b	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Relapse-free survival (RFS) •Occurence of Adverse Events •Overall survival (OS) •Distant metastases-free survival (DMFS) •Quality of life	Enrollment: 1200 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•European Organisation for Research and Treatment of Cancer - EORTC •NCIC Clinical Trials Group	•Other	Study Start: October 2012 Primary Completion: April 2019 Study Completion: April 2019 First Posted: January 2, 2012 Results First Posted: No Results Posted Last Update Posted: July 9, 2018	•Medical University of Graz, Graz, Austria •Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels, Belgium •Universitair Ziekenhuis Gent, Ghent, Belgium •U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium •Aarhus University Hospital, Aarhus, Denmark •Herlev Hospital - University Copenhagen, Herlev, Denmark •Odense University Hospital, Odense, Denmark •Assistance Publique - Hopitaux de Paris - Hopital Avicenne, Bobigny, France •CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre (Bordeaux, France, Bordeaux, France •CHU de Grenoble - La Tronche - Hôpital A. Michallon, Grenoble, France •and 48 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
15	NCT02155322	A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400) Study Documents:	Title Acronym: Other Ids: 4031-400	Completed	•Melanoma	•Biological: Pegylated Interferon Alfa-2b	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Percentage of Participants Experiencing Adverse Events (AEs) •Percentage of Participants Discontinuing Study Drug Because of AEs	Enrollment: 33 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Merck Sharp & Dohme Corp.	•Industry	Study Start: August 19, 2014 Primary Completion: March 21, 2016 Study Completion: March 21, 2016 First Posted: June 4, 2014 Results First Posted: April 11, 2017 Last Update Posted: August 23, 2018	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
16	NCT00457418	High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) Study Documents:	Title Acronym: Other Ids: P04831	Completed	•Melanoma	•Drug: PEG-Intron	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Area Under the Curve (AUC) of PEG-Intron at 12 Weeks •Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks •Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks •Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks •Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks •Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks •Number of Participants Who Experienced an Adverse Event (AE)	Enrollment: 32 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Merck Sharp & Dohme Corp.	•Industry	Study Start: February 20, 2007 Primary Completion: May 27, 2008 Study Completion: July 11, 2012 First Posted: April 6, 2007 Results First Posted: July 31, 2013 Last Update Posted: June 7, 2017	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
17	NCT00963664	Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma Study Documents:	Title Acronym: Other Ids: NI-MM-009	Withdrawn	•Melanoma •Malignant Melanoma	•Drug: lovastatin •Drug: interferon alfa-2b	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Overall survival •Time to progression of disease •Appearance of new distant metastases •Toleration of medication side effects and quality of life	Enrollment: 250 Age: 18 Years and older (Adult, Older Adult) Sex: All	•NeoPlas Innovation	•Other	Study Start: December 2009 Primary Completion: December 2016 Study Completion: December 2016 First Posted: August 21, 2009 Results First Posted: No Results Posted Last Update Posted: September 9, 2009	•NeoPlas Innovation, Nashville, Tennessee, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
18	NCT01460875	Recombinant Interferon Alfa-2b in Treating Patients With Melanoma Study Documents:	Title Acronym: Other Ids: •OSU-07033 •NCI-2011-03121	Completed	•Stage IA Skin Melanoma •Stage IB Skin Melanoma •Stage IIA Skin Melanoma •Stage IIB Skin Melanoma •Stage IIC Skin Melanoma •Stage IIIA Skin Melanoma •Stage IIIB Skin Melanoma •Stage IIIC Skin Melanoma •Stage IV Skin Melanoma	•Biological: recombinant interferon alfa-2b •Other: laboratory biomarker analysis	Study Type: Interventional Phase: Not Applicable Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Level of Activated STAT1(Phospho-STAT1) •Number of Patients With Adverse Events •Percentage of Patients With Correlation Between STAT1 Phosphorylation and Interferon Alfa Gene Regulation •Effect of Dose-reduction on Expression of Interferon Alfa Stimulated Genes •Effect of Dose-reduction on Interferon Alfa Gene Expression •Effect of Dose-reduction on Interferon Alfa Gene Expression Through Marker CD69 •Effect of Dose-reduction on Interferon Alfa Gene Expression at Dose Level 4MU •Clinical Role of Tumor Sensitivity to Recombinant Interferon Alfa-2b Using Cellular Levels of Jak-STAT Signaling Intermediates	Enrollment: 34 Age: 12 Years and older (Child, Adult, Older Adult) Sex: All	•William Carson •Schering-Plough •Ohio State University Comprehensive Cancer Center	•Other •Industry	Study Start: April 22, 2008 Primary Completion: January 5, 2014 Study Completion: January 5, 2014 First Posted: October 27, 2011 Results First Posted: November 2, 2018 Last Update Posted: November 2, 2018	•Ohio State University Medical Center, Columbus, Ohio, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
19	NCT00871533	Pilot Study of IFN #2b for Melanoma Patients Study Documents:	Title Acronym: Other Ids: 08-067	Terminated	•Melanoma	•Drug: IFN#2b •Drug: PEG- IFN#2b	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures: •To utilize gene-profiling analysis of regional lymph node tissue to molecularly characterize the effect of IFN #2b and PEG IFN#2b on the SLN. Endpoint: mRNA expression by gene array. •Quantitate putative biomarkers differentially expressed in the SLN for each active treatment group and among all active treatment groups combined. Endpoint: mRNA expression by Taqman. •Molecularly characterize the effect of perilesional IFN #2b and PEG IFN#2b administered as close as possible to the primary tumor site on SLNs that are positive vs. negative for tumor micrometastases. Endpoint: mRNA expression by gene array.	Enrollment: 50 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University of Pittsburgh •Schering-Plough	•Other •Industry	Study Start: September 2009 Primary Completion: August 2017 Study Completion: August 2017 First Posted: March 30, 2009 Results First Posted: No Results Posted Last Update Posted: August 4, 2017	•UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
20	NCT00003641	High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma Study Documents:	Title Acronym: Other Ids: •E1697 •U10CA023318 •CDR0000066727	Terminated	•Melanoma (Skin)	•Biological: interferon alfa-2b •Other: observation	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •5-year Relapse-free Survival Rate •5-year Overall Survival Rate	Enrollment: 1150 Age: 18 Years and older (Adult, Older Adult) Sex: All	•ECOG-ACRIN Cancer Research Group •National Cancer Institute (NCI) •Southwest Oncology Group •Cancer and Leukemia Group B •NCIC Clinical Trials Group •Children's Oncology Group •Eastern Cooperative Oncology Group	•Other •NIH	Study Start: December 1998 Primary Completion: January 2015 Study Completion: October 2025 First Posted: January 27, 2003 Results First Posted: May 4, 2016 Last Update Posted: May 4, 2016	•UAB Comprehensive Cancer Center, Birmingham, Alabama, United States •University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States •Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States •Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Ft. Smith, Arkansas, United States •Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States •Kaiser Permanente - Deer Valley, Antioch, California, United States •Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States •Peninsula Medical Center, Burlingame, California, United States •Southern California Permanente Medical Group, Downey, California, United States •Kaiser Permanente - Fremont, Fremont, California, United States •and 523 more
21	NCT00749684	Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083) Study Documents:	Title Acronym: Other Ids: P04083	Completed	•Melanoma	•Biological: Interferon #-2b	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Number of Participants With Disease Recurrence •Relapse Free Survival Time	Enrollment: 138 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•Merck Sharp & Dohme Corp.	•Industry	Study Start: December 1996 Primary Completion: September 2009 Study Completion: September 2009 First Posted: September 9, 2008 Results First Posted: March 24, 2011 Last Update Posted: October 19, 2015	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
22	NCT00004196	Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis Study Documents:	Title Acronym: Other Ids: •CDR0000067439 •UAB-9735 •UAB-F970925009 •NCI-G99-1654 •RPCI-DS-99-14	Completed	•Melanoma (Skin)	•Biological: recombinant interferon alfa •Procedure: lymphangiography •Drug: Observation	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Participant) •Primary Purpose: Treatment Outcome Measures:	Enrollment: 3000 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•University of Alabama at Birmingham •National Cancer Institute (NCI)	•Other •NIH	Study Start: October 1999 Primary Completion: October 2004 Study Completion: November 2007 First Posted: January 27, 2003 Results First Posted: No Results Posted Last Update Posted: January 20, 2014	•University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States •James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States •Cancer Institute of New Jersey, New Brunswick, New Jersey, United States •Roswell Park Cancer Institute, Buffalo, New York, United States
23	NCT00861406	Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine Study Documents:	Title Acronym: Other Ids: •2006-0816 •NCI-2012-01652	Completed	•Melanoma	•Drug: Pegylated Interferon-Alfa 2b (PEG Intron) •Drug: GP-100 Peptide Vaccine	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Patient Maximum T-cell Levels During 24-Week Treatment	Enrollment: 38 Age: 18 Years and older (Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center •Merck Sharp & Dohme Corp.	•Other •Industry	Study Start: March 10, 2009 Primary Completion: February 24, 2017 Study Completion: February 24, 2017 First Posted: March 13, 2009 Results First Posted: No Results Posted Last Update Posted: March 3, 2017	•University of Texas MD Anderson Cancer Center, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
24	NCT01603212	Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor Study Documents:	Title Acronym: Other Ids: •2011-0847 •NCI-2012-02759	Completed	•Melanoma	•Drug: Vemurafenib •Drug: IL-2 •Drug: Interferon Alpha-2b	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Maximum Tolerated Dose (MTD) of Vemurafenib in Combination With Interferon Alpha 2b and IL-2 •Progression-Free Survival (PFS)	Enrollment: 6 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center	•Other	Study Start: July 18, 2013 Primary Completion: July 5, 2017 Study Completion: July 5, 2017 First Posted: May 22, 2012 Results First Posted: No Results Posted Last Update Posted: July 11, 2017	•University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25	NCT01100528	Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance Study Documents:	Title Acronym: Other Ids: •CASE2609 •NCI-2010-00640	Active, not recruiting	•Ciliary Body and Choroid Melanoma, Medium/Large Size •Ciliary Body and Choroid Melanoma, Small Size •Iris Melanoma •Recurrent Intraocular Melanoma	•Biological: recombinant interferon alfa-2b •Drug: dacarbazine •Other: laboratory biomarker analysis	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Number of Patients With Disease-free Survival (DFS) •Number of Participants With Toxicity or Grade 4 Adverse Events Via CTCAE Version 3.0 •Changes in Plasma Biomarkers and Their Association With DFS	Enrollment: 38 Age: Child, Adult, Older Adult Sex: All	•Case Comprehensive Cancer Center	•Other	Study Start: November 11, 2009 Primary Completion: July 25, 2015 Study Completion: January 2019 First Posted: April 9, 2010 Results First Posted: October 29, 2018 Last Update Posted: December 7, 2018	•Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
26	NCT00003444	Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin Study Documents:	Title Acronym: Other Ids: •CDR0000066472 •E-3697	Completed	•Melanoma (Skin)	•Biological: recombinant interferon alfa •Radiation: radiation therapy	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Primary Purpose: Treatment Outcome Measures:	Enrollment: 167 Age: 18 Years and older (Adult, Older Adult) Sex: Female	•Eastern Cooperative Oncology Group •National Cancer Institute (NCI)	•Other •NIH	Study Start: October 1998 Primary Completion: September 2003 Study Completion: First Posted: May 24, 2004 Results First Posted: No Results Posted Last Update Posted: January 27, 2010	•Emory University Hospital - Atlanta, Atlanta, Georgia, United States •Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States •Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States •Veterans Affairs Medical Center - Chicago (Lakeside), Chicago, Illinois, United States •CCOP - Central Illinois, Decatur, Illinois, United States •CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States •CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States •New England Medical Center Hospital, Boston, Massachusetts, United States •Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States •CCOP - Kalamazoo, Kalamazoo, Michigan, United States •and 13 more
27	NCT00004104	Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000067323 •NYU-9837 •NCI-G99-1595	Completed	•Melanoma (Skin)	•Biological: liposomal interleukin-2 •Biological: polyvalent melanoma vaccine •Biological: recombinant interferon alfa	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Primary Purpose: Treatment Outcome Measures:	Enrollment: Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•New York University School of Medicine •National Cancer Institute (NCI)	•Other •NIH	Study Start: June 1998 Primary Completion: July 2000 Study Completion: First Posted: July 19, 2004 Results First Posted: No Results Posted Last Update Posted: March 31, 2016	•Kaplan Cancer Center, New York, New York, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
28	NCT00221702	PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/ CMII Trial) Study Documents:	Title Acronym: EADO Other Ids: •9267-01 •2001-034	Completed	•Melanoma •Neoplasm Metastasis	•Drug: PegIntron •Drug: intron A	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •disease-free survival time •time to distant metastasis •overall survival •toxicity •quality of life	Enrollment: 898 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•University Hospital, Bordeaux •Schering-Plough	•Other •Industry	Study Start: June 2003 Primary Completion: October 2010 Study Completion: October 2010 First Posted: September 22, 2005 Results First Posted: No Results Posted Last Update Posted: October 13, 2010	•APHM, dermatology, Marseille, France
29	NCT00621439	Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye Study Documents:	Title Acronym: Other Ids: IRB00002566	Withdrawn	•Ocular Melanoma	•Drug: Pegylated Interfon Alpha 2B •Drug: Placebo	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Basic Science Outcome Measures: Evidence of anti-melanoma natural killer cell boost	Enrollment: 0 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Emory University	•Other	Study Start: March 2007 Primary Completion: June 2008 Study Completion: First Posted: February 22, 2008 Results First Posted: No Results Posted Last Update Posted: December 2, 2013	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
30	NCT00238329	PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000445593 •P30CA022453 •WSU-C-2257 •WSU-HIC-120900M01-FB	Completed	•Intraocular Melanoma •Melanoma (Skin)	•Biological: PEG-interferon alfa-2b •Drug: thalidomide	Study Type: Interventional Phase: Phase 2 Study Design: •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Response rate as measured scans and tumor measurements every 8 weeks •Qualitative and quantitative toxicities at 30 days following study treatment •Progression-free survival by standard life table and Kaplan-Meier •Overall survival by standard life table and Kaplan-Meier •Vascular flow to metastatic sites by positron-emission tomography scan every 8 weeks	Enrollment: 32 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Barbara Ann Karmanos Cancer Institute •National Cancer Institute (NCI)	•Other •NIH	Study Start: January 2001 Primary Completion: December 2005 Study Completion: June 2007 First Posted: October 13, 2005 Results First Posted: No Results Posted Last Update Posted: April 8, 2013	•Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
31	NCT01708941	Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Study Documents:	Title Acronym: Other Ids: •NCI-2012-01932 •CDR0000741878 •E3611 •ECOG-E3611 •U10CA180820 •U10CA021115 •U24CA196172	Active, not recruiting	•Recurrent Melanoma •Stage IIIA Cutaneous Melanoma AJCC v7 •Stage IIIB Cutaneous Melanoma AJCC v7 •Stage IIIC Cutaneous Melanoma AJCC v7 •Stage IV Cutaneous Melanoma AJCC v6 and v7	•Biological: Ipilimumab •Other: Laboratory Biomarker Analysis •Biological: Recombinant Interferon Alfa-2b	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •PFS •Rate of regimen limiting serious adverse events (AEs), defined as grade 3 or higher immune mediated AE that require steroids or immunosuppressive therapy according to the National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0 •OS •Response rate by RECIST and by immune-related response criteria	Enrollment: 90 Age: 18 Years and older (Adult, Older Adult) Sex: All	•National Cancer Institute (NCI)	•NIH	Study Start: January 18, 2013 Primary Completion: August 8, 2017 Study Completion: First Posted: October 17, 2012 Results First Posted: No Results Posted Last Update Posted: April 4, 2018	•University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States •Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States •The Medical Center of Aurora, Aurora, Colorado, United States •Boulder Community Hospital, Boulder, Colorado, United States •Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States •Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States •Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States •Porter Adventist Hospital, Denver, Colorado, United States •Colorado Blood Cancer Institute, Denver, Colorado, United States •Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States •and 272 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
32	NCT01608594	Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-#2b for Melanoma Study Documents:	Title Acronym: Other Ids: 11-063	Completed	•Melanoma	•Drug: administration of ipilimumab10mg/kg •Drug: administration of ipilimumab 3mg/kg + HDI	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Adverse Events •Pathologic response rate •Radiologic preoperative response rate •Progression Free Survival •Overall Survival	Enrollment: 30 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Diwakar Davar •University of Pittsburgh	•Other	Study Start: May 21, 2013 Primary Completion: February 14, 2017 Study Completion: February 27, 2017 First Posted: May 31, 2012 Results First Posted: No Results Posted Last Update Posted: August 28, 2018	•UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
33	NCT01274338	Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Study Documents:	Title Acronym: Other Ids: •NCI-2011-02649 •E1609 •ECOG-E1609 •CDR0000692568 •P50CA121973 •U10CA180820 •U10CA021115 •U24CA196172	Active, not recruiting	•Melanoma of Unknown Primary •Recurrent Melanoma •Stage IIIB Cutaneous Melanoma AJCC v7 •Stage IIIC Cutaneous Melanoma AJCC v7 •Stage IV Cutaneous Melanoma AJCC v6 and v7	•Biological: Ipilimumab •Other: Quality-of-Life Assessment •Biological: Recombinant Interferon Alfa-2b	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Recurrence-free survival (RFS) •Overall survival (OS) •Incidence of toxicity assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 •Change in global quality of life assessed using the Functional Assessment of Cancer Therapy (FACT)-General (G) (patients age >= 18 only) •Change in health-related domains of quality of life assessed using symptom and functioning subscales (patients age >= 18 only)	Enrollment: 1500 Age: 12 Years and older (Child, Adult, Older Adult) Sex: All	•National Cancer Institute (NCI)	•NIH	Study Start: May 25, 2011 Primary Completion: May 1, 2020 Study Completion: First Posted: January 11, 2011 Results First Posted: No Results Posted Last Update Posted: January 7, 2019	•University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States •Providence Hospital, Mobile, Alabama, United States •University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States •Alaska Regional Hospital, Anchorage, Alaska, United States •Providence Alaska Medical Center, Anchorage, Alaska, United States •Fairbanks Memorial Hospital, Fairbanks, Alaska, United States •Banner MD Anderson Cancer Center, Gilbert, Arizona, United States •University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States •University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States •The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States •and 944 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
34	NCT02506153	High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Study Documents:	Title Acronym: Other Ids: •NCI-2014-02676 •S1404 •U10CA180888	Active, not recruiting	•Metastatic Non-Cutaneous Melanoma •Non-Cutaneous Melanoma •Recurrent Melanoma of the Skin •Recurrent Non-Cutaneous Melanoma •Stage III Cutaneous Melanoma AJCC v7 •Stage III Mucosal Melanoma of the Head and Neck AJCC v7 •Stage IIIA Cutaneous Melanoma AJCC v7 •Stage IIIB Cutaneous Melanoma AJCC v7 •Stage IIIC Cutaneous Melanoma AJCC v7 •Stage IV Cutaneous Melanoma AJCC v6 and v7 •and 3 more	•Biological: Ipilimumab •Other: Laboratory Biomarker Analysis •Biological: Pembrolizumab •Other: Pharmacological Study •Other: Quality-of-Life Assessment •Biological: Recombinant Interferon Alfa-2b	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Overall survival (OS) •Relapse-free survival (RFS) •PD-L1 status •Incidence of toxicity assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (CTCAE version 5.0 beginning April 1, 2018) •Post-relapse therapy •BRAF mutation status •Long-term survival •Change in quality of life	Enrollment: 1378 Age: 18 Years and older (Adult, Older Adult) Sex: All	•National Cancer Institute (NCI)	•NIH	Study Start: October 15, 2015 Primary Completion: September 15, 2023 Study Completion: First Posted: July 23, 2015 Results First Posted: No Results Posted Last Update Posted: January 7, 2019	•University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States •University of Arizona Cancer Center at Saint Joseph's, Phoenix, Arizona, United States •Virginia G Piper Cancer Care-Del Camino, Scottsdale, Arizona, United States •University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States •The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States •University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States •Highlands Oncology Group-Rogers, Rogers, Arkansas, United States •Kaiser Permanente-Anaheim, Anaheim, California, United States •Sutter Auburn Faith Hospital, Auburn, California, United States •Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States •and 575 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
35	NCT00613509	Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: MEL11	Terminated	•Melanoma •Cancer	•Biological: ALVAC(2) Melanoma multi-antigen therapeutic vaccine •Biological: Intron A, Interferon alpha -2b	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Summary of Disease Progression in Study Participants, Intent-to-treat Population •Progression-Free Survival Time by Response Evaluation Criteria in Solid Tumor (RECIST) Criteria in the Intent-to-treat Population •Best Overall Objective Response as Number of Participants Responding in the Intent-to-treat Population •Best Overall Objective Response in the Intent-to-treat Population •Best Overall Objective Response as Mean Duration of Response (Weeks) in the Intent-to-treat Population •Number of Participants Reporting a Grade 3 or Grade 4 Adverse Events by Preferred Term	Enrollment: 23 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Sanofi Pasteur, a Sanofi Company •Sanofi	•Industry	Study Start: June 2008 Primary Completion: April 2010 Study Completion: June 2010 First Posted: February 13, 2008 Results First Posted: December 17, 2010 Last Update Posted: April 14, 2016	•Tucson, Arizona, United States •Los Angeles, California, United States •Aurora, Colorado, United States •Atlanta, Georgia, United States •Chicago, Illinois, United States •St Louis, Missouri, United States •Omaha, Nebraska, United States •Lebanon, New Hampshire, United States •Portland, Oregon, United States •Bethlehem, Pennsylvania, United States •and 9 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
36	NCT02089685	Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/ KEYNOTE-29) Study Documents:	Title Acronym: Other Ids: •3475-029 •2013-004072-36	Active, not recruiting	•Renal Cell Carcinoma •Melanoma	•Biological: Pembrolizumab •Biological: PegIFN-2b •Biological: Ipilimumab	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Number of participants with dose-limiting toxicities (Part 1A) •Number of participants experiencing adverse events (AEs) •Number of participants discontinuing study drug because of AEs •Progression-free survival (PFS) (Part 2) •Number of participants experiencing grade 3-5 drug-related AEs (Part 1C) •Objective response rate (ORR) (Part 1C) •ORR using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Part 1C) •ORR (Part 2) •Duration of Response (DOR) (Parts 1B, 1C) •Overall Survival (OS) (Parts 1B, 1C) •and 3 more	Enrollment: 293 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Merck Sharp & Dohme Corp.	•Industry	Study Start: March 17, 2014 Primary Completion: June 17, 2020 Study Completion: June 17, 2020 First Posted: March 18, 2014 Results First Posted: No Results Posted Last Update Posted: April 3, 2018	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
37	NCT00226408	Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Study Documents:	Title Acronym: Other Ids: MM-ADJ-5	Unknown status	•Adjuvant •Stage III Malignant Melanoma •Interferon Alpha •Therapy	•Drug: Interferon-alpha-2b	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •distant metastasis free survival/(DMFI) •overall survival •time to progression •toxicity	Enrollment: 600 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•Dermatologic Cooperative Oncology Group	•Other	Study Start: November 2003 Primary Completion: Study Completion: September 2005 First Posted: September 27, 2005 Results First Posted: No Results Posted Last Update Posted: June 21, 2006	•Universitätshautklinik ,St.Josef-Hospital, Bochum, Germany •Elbekliniken Buxtehude, Buxtehude, Germany •Universitätshautklinik Essen, Essen, Germany •Universitätsklinik Eppendorf, Hamburg, Germany •Praxis, Hannover, Germany •Universitätshautklinik Heidelberg, Heidelberg, Germany •Universitätsklinikum des Saarlandes, Hautklinik, Homburg/ Saar, Germany •Christian- Albrechts-Universität ,Hautklinik, Kiel, Germany •Universitätshautklinik Köln, Köln, Germany •Universitätshautklinik Mainz, Mainz, Germany •and 3 more
38	NCT00539591	Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma Study Documents:	Title Acronym: Other Ids: •MEL06 •NCI-2011-01192	Completed	•Malignant Melanoma	•Drug: Peginterferon alfa-2b •Drug: Temozolomide •Drug: Recombinant interferon alfa-2b	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Tumor Response Rate •Number of Patients Who Experience Toxicity at or Above the Target Toxicity for Strata B1 and B2 •Number of Patients Who Experience Toxicity at or Above the Target Toxicity for Stratum A Patients •Probability of Event-free Survival (EFS) of Stratum A Participants	Enrollment: 29 Age: up to 21 Years (Child, Adult) Sex: All	•St. Jude Children's Research Hospital •Schering-Plough	•Other •Industry	Study Start: October 2007 Primary Completion: June 2015 Study Completion: October 2015 First Posted: October 4, 2007 Results First Posted: February 27, 2014 Last Update Posted: March 23, 2017	•Rady Children's Hospital, San Diego, California, United States •St. Jude Children's Research Hospital, Memphis, Tennessee, United States •The Children's Cancer Hospital at UT M.D. Anderson Cancer Center, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
39	NCT01636960	A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370) Study Documents:	Title Acronym: Other Ids: •P08556 •MK-4031-370 •132228	Terminated	•Malignant Melanoma	•Biological: PegIFN alfa-2b	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Number of Participants Experiencing Dose-limiting Toxicities (DLTs) - Induction Phase •Safety: Number of Participants Experiencing Adverse Events (AEs) •Number of Participants Discontinuing Study Drug Because of AEs	Enrollment: 9 Age: 20 Years to 75 Years (Adult, Older Adult) Sex: All	•Merck Sharp & Dohme Corp.	•Industry	Study Start: December 25, 2012 Primary Completion: March 26, 2014 Study Completion: November 4, 2015 First Posted: July 10, 2012 Results First Posted: February 11, 2015 Last Update Posted: August 8, 2018	
40	NCT02074605	Cognitive Effects of Interferon in Patients With Melanoma Study Documents:	Title Acronym: Other Ids: 08-0389-02	Completed	•Melanoma	•Biological: Interferon alpha	Study Type: Observational Phase: Study Design: •Observational Model: Case Control •Time Perspective: Prospective Outcome Measures: Change in cognitive function	Enrollment: 36 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University of Arizona	•Other	Study Start: July 2008 Primary Completion: May 2010 Study Completion: May 2010 First Posted: February 28, 2014 Results First Posted: No Results Posted Last Update Posted: February 28, 2014	•University of Arizona, Tucson, Arizona, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
41	NCT01409174	IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: •2011-0073 •NCI-2011-02768	Terminated	•Melanoma	•Drug: Ipilimumab •Drug: Temozolomide •Drug: Cisplatin •Drug: Interferon Alfa-2b •Drug: Interleukin-2	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Tumor Response by Participant using immune-related response criteria (irRC)	Enrollment: 19 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center •Bristol-Myers Squibb	•Other •Industry	Study Start: February 2013 Primary Completion: May 2016 Study Completion: May 2016 First Posted: August 4, 2011 Results First Posted: No Results Posted Last Update Posted: May 31, 2017	•University of Texas MD Anderson Cancer Center, Houston, Texas, United States
42	NCT00791271	Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion Study Documents:	Title Acronym: Other Ids: •2007-0450 •NCI-2010-01030	Terminated	•Melanoma	•Drug: Decitabine •Drug: Pegylated Interferon Alpha-2b	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Phase I: Dose-limiting toxicity (DLT) •Phase II: Patient Response	Enrollment: 17 Age: 18 Years and older (Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center •Schering-Plough •Eisai Inc.	•Other •Industry	Study Start: September 2, 2008 Primary Completion: May 2015 Study Completion: May 2015 First Posted: November 14, 2008 Results First Posted: No Results Posted Last Update Posted: November 9, 2018	•University of Texas MD Anderson Cancer Center, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
43	NCT01409187	IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: 2011-0074	Withdrawn	•Melanoma	•Drug: Ipilimumab •Drug: Interferon •Drug: Interleukin-2 (Aldesleukin)	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Progression Free survival (PFS)	Enrollment: 0 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center	•Other	Study Start: October 2011 Primary Completion: October 2016 Study Completion: First Posted: August 4, 2011 Results First Posted: No Results Posted Last Update Posted: January 26, 2012	
44	NCT01622933	Multiple Antigen-Engineered DC Vaccine for Melanoma Study Documents:	Title Acronym: Other Ids: •09-021 •1P50CA121973-01	Completed	•Melanoma	•Biological: DC Vaccine + IFN •Biological: AdVTMM2/DC Vaccination	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Safety •Immunological response (antigen-specific T cell activation)	Enrollment: 35 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Lisa H. Butterfield, Ph.D. •National Cancer Institute (NCI) •University of Pittsburgh	•Other •NIH	Study Start: June 2012 Primary Completion: May 2016 Study Completion: August 2017 First Posted: June 19, 2012 Results First Posted: No Results Posted Last Update Posted: August 31, 2017	•University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
45	NCT01986712	A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma Study Documents:	Title Acronym: Other Ids: Merck MISP 50422	Active, not recruiting	•Melanoma		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Evaluate Compliance with Standard High Dose Interferon (HDI) versus Sylatron •Compare Quality of Life (Qol)for patients on HDI versus PEG IFN •Assess the frequency of Grade 3 and Grade 4 Toxicities •Examine the Reasons for Patients' Choice of Treatment with HDI versus PEG IFN	Enrollment: 58 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Sanjiv Agarwala, MD •Merck Sharp & Dohme Corp. •St. Luke's Hospital and Health Network, Pennsylvania	•Other •Industry	Study Start: December 2013 Primary Completion: March 2021 Study Completion: March 2022 First Posted: November 18, 2013 Results First Posted: No Results Posted Last Update Posted: April 19, 2018	•Moffit Cancer Center, Tampa, Florida, United States •Roswell Park Cancer Institute, Buffalo, New York, United States •St Luke's University Hospital and Health Network, Bethlehem, Pennsylvania, United States •Huntsman Cancer Institute, Salt Lake City, Utah, United States
46	NCT00505635	Biochemotherapy With Temozolomide for Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: DM03-0218	Terminated	•Melanoma	•Drug: Temozolomide •Drug: Velban •Drug: Cisplatin •Drug: Interleukin-2 •Drug: Intron-A •Drug: Thalidomide	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Time to Progression (TTP) •Number of Participants With Response	Enrollment: 5 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center	•Other	Study Start: March 2007 Primary Completion: April 2010 Study Completion: April 2010 First Posted: July 23, 2007 Results First Posted: April 18, 2012 Last Update Posted: June 17, 2016	•U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
47	NCT00003715	Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000066824 •AVAX-A/100/0101	Terminated	•Melanoma (Skin)	•Biological: BCG vaccine •Biological: autologous tumor cell vaccine •Biological: recombinant interferon alfa •Drug: chemotherapy •Drug: cyclophosphamide	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Primary Purpose: Treatment Outcome Measures:	Enrollment: 425 Age: 18 Years to 120 Years (Adult, Older Adult) Sex: All	•AVAX Technologies	•Industry	Study Start: December 1998 Primary Completion: Study Completion: First Posted: April 23, 2004 Results First Posted: No Results Posted Last Update Posted: December 3, 2015	•Cancer and Blood Institute of the Desert, Rancho Mirage, California, United States •Yale Comprehensive Cancer Center, New Haven, Connecticut, United States •Columbia - HCA Cancer Research Network, North Miami Beach, Florida, United States •H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States •Georgia Cancer Specialists, Decatur, Georgia, United States •University of Illinois at Chicago, Chicago, Illinois, United States •Lutheran General Cancer Care Center, Park Ridge, Illinois, United States •James Graham Brown Cancer Center, Louisville, Kentucky, United States •Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States •Hubert H. Humphrey Cancer Center, Robbinsdale, Minnesota, United States •and 7 more
48	NCT00002882	Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Study Documents:	Title Acronym: Other Ids: •ID95-196 •P30CA016672 •MDA-ID-95196 •MDA-DM-95196 •NCI-G96-1089 •CDR0000065188	Completed	•Melanoma •Skin Cancer	•Biological: Aldesleukin (IL-2) •Biological: Recombinant Interferon Alfa (IFN-A) •Drug: Cisplatin •Drug: Dacarbazine •Drug: Vinblastine •Procedure: Adjuvant Therapy	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Effectiveness of Interferon Alfa with/without Combination Chemotherapy + Interleukin-2 for Melanoma	Enrollment: 140 Age: 10 Years to 70 Years (Child, Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center •National Cancer Institute (NCI)	•Other •NIH	Study Start: November 1995 Primary Completion: August 2003 Study Completion: April 2006 First Posted: January 27, 2003 Results First Posted: No Results Posted Last Update Posted: December 13, 2011	•University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
49	NCT00970996	Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma Study Documents:	Title Acronym: BCAA Other Ids: 2009-0124	Completed	•Melanoma	•Drug: Temozolomide •Drug: Abraxane •Drug: Cisplatin •Biological: Interleukin-2 •Biological: Interferon alpha 2b	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Response Rate	Enrollment: 10 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center	•Other	Study Start: September 2009 Primary Completion: December 2012 Study Completion: December 2012 First Posted: September 3, 2009 Results First Posted: No Results Posted Last Update Posted: January 3, 2013	•U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
50	NCT00610857	Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma Study Documents:	Title Acronym: Other Ids: 05-125	Completed	•Melanoma	•Drug: Anti-CTLA4 monoclonal antibody and HDI	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures: •Best Objective Response Rate (BORR) •Progression-free Survival (PFS) •1-year Overall Survival (OS) •Median Overall Survival (Point Estimate)	Enrollment: 37 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Ahmad Tarhini •Pfizer •University of Pittsburgh	•Other •Industry	Study Start: November 2006 Primary Completion: January 2015 Study Completion: January 2015 First Posted: February 8, 2008 Results First Posted: October 17, 2016 Last Update Posted: June 22, 2017	•UPCI Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
51	NCT00026143	Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma Study Documents:	Title Acronym: Other Ids: •NCI-2012-02816 •CALGB-500001 •CDR0000068990 •U10CA031946	Completed	•Recurrent Melanoma •Stage IV Melanoma	•Biological: recombinant interleukin-12 •Biological: recombinant interferon alfa •Other: laboratory biomarker analysis	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Response rate •PFS	Enrollment: 60 Age: 18 Years and older (Adult, Older Adult) Sex: All	•National Cancer Institute (NCI)	•NIH	Study Start: October 2001 Primary Completion: July 2004 Study Completion: First Posted: January 27, 2003 Results First Posted: No Results Posted Last Update Posted: June 5, 2013	•Cancer and Leukemia Group B, Chicago, Illinois, United States
52	NCT01782508	A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma Study Documents:	Title Acronym: Other Ids: AMN107A2301	Unknown status	•Melanoma	•Drug: imatinib •Drug: Interferon	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •relapse free survival •overall survival	Enrollment: 40 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Beijing Cancer Hospital	•Other	Study Start: August 2012 Primary Completion: December 2013 Study Completion: December 2014 First Posted: February 4, 2013 Results First Posted: No Results Posted Last Update Posted: February 4, 2013	•Beijing Cancer Hospital, Beijing, China

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
53	NCT00002763	High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000064718 •EORTC-18952	Unknown status	•Melanoma (Skin)	•Biological: recombinant interferon alfa	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Primary Purpose: Treatment Outcome Measures:	Enrollment: 1000 Age: 16 Years to 75 Years (Child, Adult, Older Adult) Sex: All	•European Organisation for Research and Treatment of Cancer - EORTC •National Cancer Institute (NCI)	•Other	Study Start: April 1996 Primary Completion: Study Completion: First Posted: July 19, 2004 Results First Posted: No Results Posted Last Update Posted: November 16, 2011	•Krankenhaus der Elisabethinen, Linz, Austria •Landeskrankenanstalten - Salzburg, Salzburg, Austria •Institut Jules Bordet, Brussels (Bruxelles), Belgium •Cliniques Universitaires Saint-Luc, Brussels (Bruxelles), Belgium •Hopital Universitaire Erasme, Brussels, Belgium •Centre Hospitalier Notre Dame - Reine Fabiola, Charleroi, Belgium •Universitair Ziekenhuis Antwerpen, Edegem, Belgium •Universitair Ziekenhuis Gent, Ghent (Gent), Belgium •U.Z. Gasthuisberg, Leuven, Belgium •Alexander's University Hospital, Sofia, Bulgaria •and 76 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
54	NCT00026520	Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000069046 •SWOG-S0026	Completed	•Melanoma (Skin)	•Biological: recombinant interferon alfa •Drug: thalidomide	Study Type: Interventional Phase: Phase 2 Study Design: Primary Purpose: Treatment Outcome Measures:	Enrollment: Age: 18 Years and older (Adult, Older Adult) Sex: All	•Southwest Oncology Group •National Cancer Institute (NCI)	•Other •NIH	Study Start: November 2001 Primary Completion: Study Completion: April 2006 First Posted: June 25, 2003 Results First Posted: No Results Posted Last Update Posted: June 24, 2013	•MBCCOP - Gulf Coast, Mobile, Alabama, United States •CCOP - Greater Phoenix, Phoenix, Arizona, United States •Veterans Affairs Medical Center - Phoenix (Hayden), Phoenix, Arizona, United States •Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States •Arizona Cancer Center, Tucson, Arizona, United States •University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States •Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States •Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States •USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States •Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States •and 84 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
55	NCT00026221	Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma Study Documents:	Title Acronym: Other Ids: •NCI-2009-00006 •CDR0000069010 •2001C0185 •OSU-01H0185 •0132 •NCI-2669 •OSU 0132 •2669 •N01CM62207 •R21CA093071 •P30CA016058	Completed	•Recurrent Melanoma •Stage IV Skin Melanoma	•Biological: Recombinant Interferon Alfa •Biological: Bevacizumab	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Objective Response Rate •Progression-free Survival •Comparison of Plasma Levels of VEGF Following Administration of Bevacizumab Alone or in Combination With IFN-alfa •New Vessel Formation in Patient Tumor Samples	Enrollment: 57 Age: 18 Years and older (Adult, Older Adult) Sex: All	•National Cancer Institute (NCI)	•NIH	Study Start: November 2001 Primary Completion: November 2013 Study Completion: November 2013 First Posted: January 27, 2003 Results First Posted: March 17, 2016 Last Update Posted: March 17, 2016	•University of Cincinnati, Cincinnati, Ohio, United States •Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
56	NCT00002767	Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000064732 •CORIXA-2885-14 •RIR-2885-14 •YALE-HIC-8666 •NCI-V96-0883	Unknown status	•Melanoma (Skin)	•Biological: Detox-B adjuvant •Biological: recombinant interferon alfa	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Primary Purpose: Treatment Outcome Measures:	Enrollment: 300 Age: 18 Years and older (Adult, Older Adult) Sex: All	•GlaxoSmithKline •National Cancer Institute (NCI)	•Industry	Study Start: January 1996 Primary Completion: Study Completion: First Posted: September 2, 2004 Results First Posted: No Results Posted Last Update Posted: January 6, 2014	•University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States •Beckman Research Institute, City of Hope, Duarte, California, United States •University of California San Diego Cancer Center - La Jolla, La Jolla, California, United States •Kaiser Permanente Medical Center - Oakland, Oakland, California, United States •Kaiser Permanente Medical Center-Sacramento, Sacramento, California, United States •UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States •Kaiser Permanente Medical Group - San Francisco, San Francisco, California, United States •Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States •Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States •University of Connecticut Health Center, Farmington, Connecticut, United States •and 17 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
57	NCT00006237	S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Study Documents:	Title Acronym: Other Ids: •S0008 •U10CA032102 •CALGB-500002 •ECOG-S0008 •COG-S0008	Completed	•Melanoma (Skin)	•Biological: interleukin-2 •Biological: filgrastim •Biological: interferon alfa •Drug: cisplatin •Drug: dacarbazine •Drug: vinblastine	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •5-year Overall Survival •5-year Relapse-Free Survival •Toxicity	Enrollment: 432 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Southwest Oncology Group •National Cancer Institute (NCI) •Eastern Cooperative Oncology Group •Cancer and Leukemia Group B •Children's Oncology Group	•Other •NIH	Study Start: August 2000 Primary Completion: July 2012 Study Completion: July 2012 First Posted: January 27, 2003 Results First Posted: September 19, 2012 Last Update Posted: March 25, 2015	•Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States •Mobile Infirmary Medical Center, Mobile, Alabama, United States •Banner Thunderbird Medical Center, Glendale, Arizona, United States •Banner Good Samaritan Medical Center, Phoenix, Arizona, United States •CCOP - Western Regional, Arizona, Phoenix, Arizona, United States •Phoenix Children's Hospital, Phoenix, Arizona, United States •Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States •Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Ft. Smith, Arkansas, United States •Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States •Eden Medical Center, Castro Valley, California, United States •and 287 more
58	NCT00027742	Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Study Documents:	Title Acronym: Other Ids: •01-005 •CDR0000069062 •NCI-G01-2031	Completed	•Intraocular Melanoma •Melanoma (Skin)	•Biological: pegylated interferon alfa •Drug: temozolomide	Study Type: Interventional Phase: Phase 2 Study Design: Primary Purpose: Treatment Outcome Measures:	Enrollment: Age: 18 Years and older (Adult, Older Adult) Sex: All	•Memorial Sloan Kettering Cancer Center •National Cancer Institute (NCI)	•Other •NIH	Study Start: May 2001 Primary Completion: June 2005 Study Completion: June 2005 First Posted: January 27, 2003 Results First Posted: No Results Posted Last Update Posted: June 5, 2013	•Memorial Sloan-Kettering Cancer Center, New York, New York, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
59	NCT00014092	Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery Study Documents:	Title Acronym: Other Ids: •CDR0000067958 •SFMH-BB-IND-5301 •NCI-V00-1591	Completed	•Melanoma (Skin)	•Biological: aldesleukin •Biological: recombinant interferon alfa •Biological: sargramostim •Drug: temozolomide	Study Type: Interventional Phase: Phase 2 Study Design: Primary Purpose: Treatment Outcome Measures:	Enrollment: Age: 18 Years and older (Adult, Older Adult) Sex: All	•Saint Francis Memorial Hospital •National Cancer Institute (NCI)	•Other	Study Start: December 1999 Primary Completion: Study Completion: December 2003 First Posted: January 27, 2003 Results First Posted: No Results Posted Last Update Posted: March 26, 2013	•Saint Francis Memorial Hospital, San Francisco, California, United States •John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, United States •University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora, Colorado, United States
60	NCT00897546	Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000489213 •ECOG-E1L06T1	Completed	•Melanoma (Skin)	•Other: laboratory biomarker analysis	Study Type: Observational Phase: Study Design: •Observational Model: Other •Time Perspective: Retrospective Outcome Measures: •Generation of a comprehensive multiplexed array of melanoma-associated serological markers •Changes in the profile of serological markers induced by interferon-alfa 2b therapy •Panels of serological markers with prognostic and predictive power for interferon-alfa 2b response	Enrollment: 1716 Age: 18 Years to 120 Years (Adult, Older Adult) Sex: All	•ECOG-ACRIN Cancer Research Group •National Cancer Institute (NCI) •Eastern Cooperative Oncology Group	•Other •NIH	Study Start: June 1, 2007 Primary Completion: July 1, 2008 Study Completion: July 1, 2008 First Posted: May 12, 2009 Results First Posted: No Results Posted Last Update Posted: May 19, 2017	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
61	NCT00003091	High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000065795 •CBRG-9509 •NBSG-9509 •NCI-V97-1346	Completed	•Kidney Cancer •Melanoma (Skin)	•Biological: aldesleukin •Biological: recombinant interferon alfa	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures:	Enrollment: 40 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Hoag Memorial Hospital Presbyterian •Cancer Biotherapy Research Group	•Other	Study Start: January 1996 Primary Completion: January 2000 Study Completion: January 2000 First Posted: July 7, 2004 Results First Posted: No Results Posted Last Update Posted: May 12, 2011	•Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States •Bloomington Hospital, Bloomington, Indiana, United States •Baptist Regional Cancer Center - Knoxville, Knoxville, Tennessee, United States •St. Joseph Regional Cancer Center, Bryan, Texas, United States
62	NCT00398450	Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000511743 •UCSD-060199 •PHARMION-UCSD-060199	Unknown status	•Melanoma (Skin)	•Biological: recombinant interferon alfa-2b •Drug: azacitidine	Study Type: Interventional Phase: Phase 1 Study Design: Primary Purpose: Treatment Outcome Measures: •Maximum tolerated dose •Toxicity •Response •Survival at day 1, 12 months, 3 years, and 5 years •Relapse-free survival •Time to relapse	Enrollment: 12 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University of California, San Diego •National Cancer Institute (NCI)	•Other •NIH	Study Start: February 2006 Primary Completion: May 2007 Study Completion: First Posted: November 10, 2006 Results First Posted: No Results Posted Last Update Posted: February 9, 2009	•Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
63	NCT00006249	Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Study Documents:	Title Acronym: Other Ids: EORTC-18991	Unknown status	•Melanoma (Skin)	•Biological: pegylated interferon alfa •Procedure: adjuvant therapy	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •distant-metastasis free-survival (DMFS) •survival •toxicity	Enrollment: 1258 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•European Organisation for Research and Treatment of Cancer - EORTC	•Other	Study Start: June 2000 Primary Completion: August 2003 Study Completion: First Posted: January 27, 2003 Results First Posted: No Results Posted Last Update Posted: February 10, 2015	•Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia •Austin and Repatriation Medical Centre, Heidelberg West, Victoria, Australia •Royal Perth Hospital, Perth, Western Australia, Australia •Sir Charles Gairdner Hospital, Perth, Perth, Western Australia, Australia •David Maddison Clincial Sciences, Newcastle, Australia •Institut Jules Bordet, Brussels, Belgium •Hopital Universitaire Erasme, Brussels, Belgium •Cliniques Universitaires Saint-Luc, Brussels, Belgium •Universitair Ziekenhuis Antwerpen, Edegem, Belgium •Clinique Notre Dame de Grace, Gosselies, Belgium •and 94 more
64	NCT00629200	Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies Study Documents:	Title Acronym: Other Ids: •2006-0354 •NCI-2010-01525	Completed	•Advanced Cancer •Solid Tumors	•Drug: Sodium Stibogluconate •Drug: Interferon Alpha-2b	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Maximum tolerated dose (MTD) of SSG in combination with IFN alpha2b	Enrollment: 33 Age: 18 Years and older (Adult, Older Adult) Sex: All	•M.D. Anderson Cancer Center •VioQuest Pharmaceuticals	•Other •Industry	Study Start: September 13, 2006 Primary Completion: February 10, 2010 Study Completion: February 10, 2010 First Posted: March 5, 2008 Results First Posted: No Results Posted Last Update Posted: November 15, 2018	•University of New Mexico, Albuquerque, New Mexico, United States •U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
65	NCT00004141	Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: •9372 •UCCRC-9372 •UCCRC-CTRC-9821 •NCI-G99-1615	Completed	•Melanoma (Skin)	•Drug: Cisplatin •Drug: dacarbazine •Drug: Granulocyte-macrophage colony-stimulating factor	Study Type: Interventional Phase: Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Objective response rate	Enrollment: 46 Age: Child, Adult, Older Adult Sex: All	•University of Chicago •National Cancer Institute (NCI)	•Other •NIH	Study Start: August 1998 Primary Completion: January 2003 Study Completion: April 2006 First Posted: January 27, 2003 Results First Posted: No Results Posted Last Update Posted: September 5, 2013	•University of Chicago Cancer Research Center, Chicago, Illinois, United States
66	NCT00006385	Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000068263 •E-1696	Completed	•Melanoma (Skin)	•Biological: MART-1 antigen •Biological: gp100 antigen •Biological: incomplete Freund's adjuvant •Biological: recombinant interferon alfa •Biological: sargramostim •Biological: tyrosinase peptide	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Primary Purpose: Treatment Outcome Measures:	Enrollment: Age: 18 Years and older (Adult, Older Adult) Sex: All	•Eastern Cooperative Oncology Group •National Cancer Institute (NCI)	•Other •NIH	Study Start: September 2000 Primary Completion: October 2006 Study Completion: First Posted: January 27, 2003 Results First Posted: No Results Posted Last Update Posted: November 8, 2011	•CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States •Emory University Hospital - Atlanta, Atlanta, Georgia, United States •Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States •Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States •Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States •CCOP - Evanston, Evanston, Illinois, United States •CCOP - Carle Cancer Center, Urbana, Illinois, United States •Indiana University Cancer Center, Indianapolis, Indiana, United States •Veterans Affairs Medical Center - Indianapolis (Roudebush), Indianapolis, Indiana, United States •CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States •and 22 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
67	NCT00003266	Methylphenidate in Treating Patients With Melanoma Study Documents:	Title Acronym: Other Ids: •CDR0000066161 •E-2Z96 •NCI-P98-0130	Completed	•Fatigue •Unspecified Adult Solid Tumor, Protocol Specific	•Drug: methylphenidate hydrochloride •Procedure: quality-of-life assessment	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Masking: Double •Primary Purpose: Supportive Care Outcome Measures:	Enrollment: 200 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Eastern Cooperative Oncology Group •National Cancer Institute (NCI)	•Other •NIH	Study Start: June 1999 Primary Completion: May 2002 Study Completion: First Posted: October 28, 2003 Results First Posted: No Results Posted Last Update Posted: May 8, 2012	•CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States •Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States •Stanford University Medical Center, Stanford, California, United States •CCOP - Colorado Cancer Research Program, Inc., Denver, Colorado, United States •Veterans Affairs Medical Center - Gainsville, Gainesville, Florida, United States •H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States •Veterans Affairs Medical Center - Tampa (Haley), Tampa, Florida, United States •Emory University Hospital - Atlanta, Atlanta, Georgia, United States •Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States •Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States •and 49 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
68	NCT01496807	Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma Study Documents:	Title Acronym: Other Ids: MCC-16755	Completed	•Melanoma	•Drug: Sylatron •Drug: Yervoy	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Maximum Tolerated Dose (MTD) of Sylatron •Maximum Tolerated Dose (MTD) of Ipilimumab •Number of Participants With Overall Response (OR) •Progression Free Survival (PFS) •Overall Survival (OS) •Treatment Related Adverse Events (AEs) - Grade 3 to 5	Enrollment: 31 Age: 16 Years and older (Child, Adult, Older Adult) Sex: All	•H. Lee Moffitt Cancer Center and Research Institute •Merck Sharp & Dohme Corp.	•Other •Industry	Study Start: February 17, 2012 Primary Completion: March 16, 2016 Study Completion: August 29, 2016 First Posted: December 21, 2011 Results First Posted: April 28, 2017 Last Update Posted: April 28, 2017	•H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
69	NCT01359956	Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma Study Documents:	Title Acronym: SICOG 0109 Other Ids: SICOG 0109	Completed	•Malignant Melanoma •Recurrent Melanoma	•Drug: Dacarbazine •Drug: Fotemustine •Drug: Interferon Alfa-2b	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Factorial Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •overall survival •progression free survival •Response rate •treatment related toxicity	Enrollment: 269 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•National Cancer Institute, Naples	•Other	Study Start: April 2002 Primary Completion: February 2011 Study Completion: February 2011 First Posted: May 25, 2011 Results First Posted: No Results Posted Last Update Posted: April 3, 2014	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
70	NCT02379195	Peginterferon and TIL Therapy for Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: MM1413	Active, not recruiting	•Metastatic Melanoma	•Drug: Cyclophosphamide •Drug: Fludarabine •Biological: TIL infusion •Drug: Interleukin-2 •Drug: Peginterferon alfa-2b	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Number and type of reported adverse events •Treatment related immune responses •Objective response rate •Overall survival •Progression free survival	Enrollment: 12 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•Inge Marie Svane •Herlev Hospital	•Other	Study Start: November 2014 Primary Completion: January 2018 Study Completion: January 2020 First Posted: March 4, 2015 Results First Posted: No Results Posted Last Update Posted: March 19, 2018	•Center for Cancer Immune Therapy, Dept. of Haematology/Oncology, Copenhagen, Herlev, Denmark
71	NCT02112032	Treatment of Advanced Melanoma With MK-3475 and Peginterferon Study Documents:	Title Acronym: Other Ids: 13-105	Active, not recruiting	•Melanoma	•Drug: MK-3475 •Drug: Peginterferon alfa-2b	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Number of Participants with Serious and Non-Serious Adverse Events •Time to Disease Progression	Enrollment: 43 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Hassane M. Zarour, MD •Merck Sharp & Dohme Corp. •Melanoma Research Alliance •University of Pittsburgh	•Other •Industry	Study Start: August 2014 Primary Completion: April 2019 Study Completion: December 2023 First Posted: April 11, 2014 Results First Posted: No Results Posted Last Update Posted: October 10, 2018	•Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
72	NCT00339222	Family Study of Melanoma in Italy Study Documents:	Title Acronym: Other Ids: •999902038 •02-C-N038	Recruiting	•Melanoma •Dysplastic Nevi •Melanocytic Nevi		Study Type: Observational Phase: Study Design: •Observational Model: Family-Based •Time Perspective: Other Outcome Measures: Defining the clinical spectrum and natural history of familial melanoma and susceptibility states over multiple generations	Enrollment: 1600 Age: 10 Years to 100 Years (Child, Adult, Older Adult) Sex: All	•National Cancer Institute (NCI) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: November 5, 2001 Primary Completion: Study Completion: First Posted: June 21, 2006 Results First Posted: No Results Posted Last Update Posted: December 24, 2018	•Ospedale Maurizio Bufalini Cesena, Italy, Cessana, Italy •University of Genoa, Genoa, Italy •University of L'Aquila, L'Aquila, Italy •Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy •Istituto Oncologico Veneto IRCCS University of Padua, Padova, Italy •Hospital Clinic of Barcelona (Centre de Diagnostic Biomedic), Barcelona, Spain •Instituto Valenciano de Oncologia, Valencia, Spain
73	NCT03178123	The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery Study Documents:	Title Acronym: Other Ids: Junshi-JS001-010	Recruiting	•Mucosal Melanoma	•Biological: humanized anti-PD-1 monoclonal antibody •Biological: high-dose recombinant interferon a-2B	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Recurrence-free survival rate •Distant metastases-free survival •recurrence - free survival rate at 3 years •Overall survival (OS) •Number of participants with treatment-related adverse events	Enrollment: 220 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•Shanghai Junshi Bioscience Co.,Ltd.	•Other	Study Start: May 31, 2017 Primary Completion: April 30, 2022 Study Completion: April 30, 2025 First Posted: June 6, 2017 Results First Posted: No Results Posted Last Update Posted: September 6, 2018	•Beijing Cancer Hospital, Beijing, Beijing, China

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
74	NCT00311558	Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma Study Documents:	Title Acronym: Other Ids: •CASE-CCF-7059 •P30CA043703 •CASE-CCF-7509 •CASE-CCF-1062 •CASE 2Y06	Terminated	•Cancer	•Biological: recombinant interferon alfa-2b •Drug: sodium stibogluconate •Drug: SSG & interferon	Study Type: Interventional Phase: Phase 1 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Tolerance, safety, and maximum tolerated dose at 1 week after each course	Enrollment: 18 Age: 18 Years to 120 Years (Adult, Older Adult) Sex: All	•The Cleveland Clinic •National Cancer Institute (NCI)	•Other •NIH	Study Start: October 2005 Primary Completion: May 2011 Study Completion: January 2012 First Posted: April 6, 2006 Results First Posted: No Results Posted Last Update Posted: January 26, 2018	•Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
75	NCT00679289	Phase II Study of KW2871 Combined With High Dose Interferon-#2b in Patients With Metastatic Melanoma Study Documents:	Title Acronym: Other Ids: •LUD2007-001 •UPCI07-023 •UCH15689B	Completed	•Metastatic Melanoma •Cutaneous Melanoma	•Drug: HDI •Drug: KW2871	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Median Progression-free Survival (PFS) With 95% Confidence Intervals •Number of Patients With Treatment-emergent Adverse Events (TEAEs) •Number of Patients With Best Overall Tumor Response •Number of Patients With Human Antichimeric Antibody (HACA) Reactivity To KW2871 •Maximum KW2871 Antibody Levels in Plasma Following the First Infusion	Enrollment: 36 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Ludwig Institute for Cancer Research •University of Pittsburgh •University of Chicago •Life Science Pharmaceuticals	•Other	Study Start: March 28, 2008 Primary Completion: February 3, 2014 Study Completion: February 3, 2014 First Posted: May 16, 2008 Results First Posted: February 9, 2018 Last Update Posted: March 16, 2018	•University of Chicago Hospital, Chicago, Illinois, United States •University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
76	NCT02794636	Interferon Toxicities in Melanoma Treatment Study Documents:	Title Acronym: ITMT Other Ids: CA184-404	Completed	•Stage III Melanoma		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Retrospective Outcome Measures: •Prevalence of depression in patients with stage III melanoma before initiation of Interferon alfa-2b (IFN) therapy •Prevalence of depression in patients with stage III melanoma after initiation of IFN therapy •Prevalence of fatigue in patients with stage III melanoma before initiation of IFN therapy •Prevalence of fatigue in patients with stage III melanoma after initiation of IFN therapy •Prevalence of myalgia in patients with stage III melanoma before initiation of IFN therapy •Prevalence of myalgia in patients with stage III melanoma after initiation of IFN therapy •Pre-IFN treatment period Health care costs related to depression •Post-IFN treatment period Health care costs related to depression •Pre-IFN treatment period Health care costs related to fatigue •Post-IFN treatment period Health care costs related to fatigue •Pre-IFN treatment period Health care costs related to myalgia •Post-IFN treatment period Health care costs related to myalgia	Enrollment: 436 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Bristol-Myers Squibb	•Industry	Study Start: May 2014 Primary Completion: November 2015 Study Completion: November 2015 First Posted: June 9, 2016 Results First Posted: No Results Posted Last Update Posted: June 9, 2016	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
77	NCT01743157	Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma Study Documents:	Title Acronym: BBI Other Ids: BBI Total Therapy	Completed	•Metastatic Melanoma	•Drug: Biochemo + bevacizumab then ipilimumab	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy and Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)	Enrollment: 24 Age: 18 Years and older (Adult, Older Adult) Sex: All	•California Pacific Medical Center Research Institute	•Other	Study Start: December 2010 Primary Completion: May 2013 Study Completion: May 2013 First Posted: December 6, 2012 Results First Posted: No Results Posted Last Update Posted: August 29, 2013	•San Francisco Oncology Associates, San Francisco, California, United States